MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

RESULTS FORECAST FOR THE FIRST HALF OF 2026

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**" or "**our**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, due to the Group's completion of the acquisition of the cardiac rhythm management (the "**CRM**") business on December 19, 2025 (the "**Acquisition**"), the CRM business is fully consolidated into the Group's financial statements for the six months ended June 30, 2026 (the "**Reporting Period**") for the first time, and based on a preliminary review of the unaudited consolidated management accounts of the Group for the Reporting Period, and an assessment of the latest information currently available to the Board, the Group is expected to record revenue of not less than US$153 million and a net loss of not more than US$25 million for the Reporting Period.

During the Reporting Period, the Group's global CRM business maintained steady growth, in which the implantation volume of cardiac pacemakers recorded double digit growth in Chinese market. Meanwhile, leveraging the mature channels and resources of the CRM business in global registration and commercialization, the commercialization of VitaFlow Liberty® transcatheter aortic valve implantation system has accelerated in regions covered by the CE Mark, and the registrations and sales in emerging countries have expanded concurrently, achieving an increase of over 350% in over 40 countries of non-China market implantations compared with the six months ended June 30, 2025, including a single-month implantation record of over 250 units. In addition, the Group has implemented a series of integration measures to continuously unlock synergies following the completion of the Acquisition, and has also further deepened cost-reduction and expense-control initiatives to improve operational efficiency and cut various operating costs.

As the Company is still in the process of finalising the interim results of the Group for the Reporting Period, the information contained in this announcement is only based on a preliminary assessment of the unaudited consolidated management accounts and relevant revenue and expense estimates made available to the Board as of the date of this announcement, which have not been audited or reviewed by the Company's auditors or reviewed by the audit committee of the Company, and the above information may be subject to adjustments. The actual financial results of the Group for the Reporting Period may differ from what is disclosed in this announcement. Further details of the Group's financial information will be disclosed in the Group's interim results announcement for the Reporting Period, which is expected to be published in August 2026 according to the Listing Rules. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC
August 11, 2026

As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang and Mr. Deng Aoyi, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang, Dr. Hu Bingshan and Mr. Mao Junxiang.